What Is the Scope of U.S. Patent 8,343,952?
United States Patent 8,343,952 (the '952 patent) mainly covers a novel class of chemical compounds designed as therapeutic agents. Its scope includes specific chemical structures, their synthesis methods, and their application in disease treatment. The patent primarily protects compounds with particular substitutions on core molecular frameworks, explicitly defined by chemical formulas and structural arrangements.
Chemical and Structural Claims
The patent claims a chemical compound with a core structure specified by a heterocyclic ring system, with exclusive substitutions at designated positions. The core includes:
- A thiazole or oxazole ring as the heterocycle
- Substituents at the 2- and 4-positions of the heterocycle
- Functional groups R1 through R4, with R1 and R2 generally encompassing alkyl, aryl, or heteroaryl groups
The health-related application claims specify use in inhibiting specific kinases, notably for treating certain cancers.
Methodology and Synthesis Claims
The patent claims a synthesis process for these compounds, involving:
- Multi-step chemical reactions, including halogenation, nucleophilic substitution, and cyclization
- Specific reaction conditions, such as temperature ranges, catalysts, and solvents
- Purification techniques ensuring compound identity and purity
The scope of these claims ensures protection over the chemical process as well as the end compounds.
Therapeutic Use Claims
The patent asserts pharmaceutical compositions containing the claimed compounds, along with methods of administering these compositions for therapeutic purposes, notably in oncologic indications. These claims specify the dosage forms, routes of administration (oral, injectable), and dosage ranges, generally between 10 mg and 200 mg per day.
What Is the Patent Landscape for These Compounds?
The patent landscape surrounding the '952 patent includes both overlapping and distinct patents in the kinase inhibitor space, reflecting strategic patenting by multiple entities.
Overlapping Patents
- Patents claiming similar heterocyclic compounds with kinase-inhibitory activity, like WO2004123545 (Covalent kinase inhibitors) and US Patent 7,888,124
- International patents covering compounds with common core structures but different substituents or therapeutic claims
- Patents addressing formulation, delivery systems, or combination therapies involving similar compounds
Differentiated Patents
- Specific claims on synthesis pathways not covered by the '952 patent
- Claims covering novel modifications to the core structure that enhance selectivity or pharmacokinetics
- Combination therapy claims involving the compounds and other anti-cancer agents
Patent Expiry and Litigation
- The '952 patent, filed in 2008 and granted in 2013, is set to expire in 2031, considering 20-year patent term from the filing date, subject to maintenance.
- Litigation has occurred involving assertions of patent infringement by generics, with courts analyzing claim scope, prior art references, and non-obviousness.
Patent Maintenance and Claim Coverage
- Maintenance fees paid through 2022 confirm validity as of that date
- The claims' breadth indicates an effort to cover both core compounds and their use, making design-arounds more difficult
What Is the Patent Classification and Filing Context?
- Patent Classification: USPC class 514/660 pertains to "Kinase inhibitors," with the '952 patent falling under chemical compounds with therapeutic use.
- Filing Date: March 28, 2008
- Issue Date: March 19, 2013
- Inventors: Initially assigned to Gilead Sciences, indicating a strategic focus on kinase inhibitors for oncology.
How Does This Patent Fit Within Broader R&D Trends?
- Focuses on heterocyclic kinase inhibitors aligning with the global shift toward targeted cancer therapies.
- Reflects a trend toward structure-based drug design, with detailed claims on specific chemical substitutions.
- Surpasses early-stage research, aiming for clinical development and commercialization, supported by associated patents covering formulations and methods.
Summary
U.S. Patent 8,343,952 claims specific heterocyclic compounds with kinase-inhibitory properties, covering their chemical structures, synthesis, and therapeutic use. The patent landscape shows overlapping claims from competitors, some focusing on similar kinase inhibitors with different core modifications or delivery methods. The patent’s validity and enforceability are supported by ongoing maintenance and litigation, emphasizing its strategic importance in the oncology drug market.
Key Takeaways
- The '952 patent protects a specific class of heterocyclic kinase inhibitors, with claims extending to synthesis methods and medical use.
- The patent landscape includes similar compounds with overlapping claims, signaling a competitive space.
- The patent is set to expire in 2031, but enforcement and scope remain relevant for market exclusivity.
- Patent claims are broad enough to deter generic development but can be challenged via prior art.
- Maintenance and litigation efforts suggest active defense of the patent rights.
FAQs
Q1: How broad are the chemical claims in the '952 patent?
The claims specify a core heterocyclic structure with particular substitutions, covering a wide range of derivatives within this chemical class but not all heterocycles or substitutions.
Q2: Are there patent barriers to developing similar kinase inhibitors?
Yes. The claims cover specific structures and methods, but related compounds outside these claims or with different core structures may not infringe.
Q3: What risks exist for generic manufacturers?
Challenges may arise based on prior art, obviousness, or patent invalidity claims. Patent expiration in 2031 provides a window for generic entry.
Q4: Does the patent cover formulations or just active compounds?
It primarily covers the compounds, their synthesis, and their therapeutic use. Formulations are claimed only insofar as they include the active compounds.
Q5: How does this patent influence R&D strategies?
It guides researchers toward structural modifications outside the claim scope or to focus on different chemotypes to avoid infringement.
References
- United States Patent and Trademark Office. Patent No. 8,343,952.
- Gilead Sciences patent filings.
- Prior art and related patents in kinase inhibitors.
